Utah Medical Products, Inc. (UTMD)
USD 58.17
(-0.73%)
USD 58.17
(-0.73%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 295 Thousand USD | -13.49% |
| 2022 | 341 Thousand USD | 3.02% |
| 2021 | 331 Thousand USD | -1.19% |
| 2020 | 335 Thousand USD | -10.9% |
| 2019 | 376 Thousand USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | -100.0% |
| 2014 | 973 Thousand USD | -80.79% |
| 2013 | 5.06 Million USD | -33.38% |
| 2012 | 7.6 Million USD | -53.19% |
| 2011 | 16.24 Million USD | 1686.8% |
| 2010 | 909 Thousand USD | -35.21% |
| 2009 | 1.4 Million USD | -23.25% |
| 2008 | 1.82 Million USD | -50.45% |
| 2007 | 3.68 Million USD | -15.83% |
| 2006 | 4.38 Million USD | -17.86% |
| 2005 | 5.33 Million USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | -100.0% |
| 2002 | 4.95 Million USD | 98.16% |
| 2001 | 2.5 Million USD | -74.99% |
| 2000 | 10 Million USD | 68.52% |
| 1999 | 5.93 Million USD | 91.42% |
| 1998 | 3.1 Million USD | -44.64% |
| 1997 | 5.6 Million USD | 0.0% |
| 1996 | - USD | 0.0% |
| 1995 | - USD | 0.0% |
| 1994 | - USD | 0.0% |
| 1993 | - USD | 0.0% |
| 1992 | - USD | 0.0% |
| 1991 | - USD | 0.0% |
| 1990 | - USD | -100.0% |
| 1989 | 100 Thousand USD | -87.5% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 285 Thousand USD | 0.0% |
| 2024 Q3 | - USD | 0.0% |
| 2024 Q2 | 275 Thousand USD | 0.0% |
| 2023 Q2 | 315 Thousand USD | -3.96% |
| 2023 Q4 | 295 Thousand USD | -3.28% |
| 2023 Q3 | 305 Thousand USD | -3.17% |
| 2023 Q1 | 328 Thousand USD | -3.81% |
| 2023 FY | 295 Thousand USD | -13.49% |
| 2022 Q3 | 354 Thousand USD | -3.8% |
| 2022 Q1 | 382 Thousand USD | 15.41% |
| 2022 FY | 341 Thousand USD | 3.02% |
| 2022 Q4 | 341 Thousand USD | -3.67% |
| 2022 Q2 | 368 Thousand USD | -3.66% |
| 2021 Q1 | 329 Thousand USD | -1.79% |
| 2021 Q2 | 322 Thousand USD | -2.13% |
| 2021 Q4 | 331 Thousand USD | -3.5% |
| 2021 FY | 331 Thousand USD | -1.19% |
| 2021 Q3 | 343 Thousand USD | 6.52% |
| 2020 FY | 335 Thousand USD | -10.9% |
| 2020 Q1 | 366 Thousand USD | -2.66% |
| 2020 Q2 | 356 Thousand USD | -2.73% |
| 2020 Q3 | 346 Thousand USD | -2.81% |
| 2020 Q4 | 335 Thousand USD | -3.18% |
| 2019 Q3 | 385 Thousand USD | -2.53% |
| 2019 Q2 | 395 Thousand USD | -2.47% |
| 2019 Q1 | 405 Thousand USD | 0.0% |
| 2019 FY | 376 Thousand USD | 0.0% |
| 2019 Q4 | 376 Thousand USD | -2.34% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 FY | - USD | -100.0% |
| 2015 Q1 | - USD | -100.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2014 FY | 973 Thousand USD | -80.79% |
| 2014 Q4 | 973 Thousand USD | -51.3% |
| 2014 Q2 | 3.1 Million USD | -23.73% |
| 2014 Q1 | 4.06 Million USD | -19.7% |
| 2014 Q3 | 1.99 Million USD | -35.59% |
| 2013 FY | 5.06 Million USD | -33.38% |
| 2013 Q3 | 5.98 Million USD | -10.82% |
| 2013 Q2 | 6.7 Million USD | -12.45% |
| 2013 Q1 | 7.66 Million USD | -14.88% |
| 2013 Q4 | 5.06 Million USD | -15.34% |
| 2012 Q2 | 11.15 Million USD | -20.57% |
| 2012 FY | 7.6 Million USD | -53.19% |
| 2012 Q3 | 9.41 Million USD | -15.59% |
| 2012 Q1 | 14.04 Million USD | -13.55% |
| 2012 Q4 | 9 Million USD | -4.38% |
| 2011 Q4 | 16.24 Million USD | -12.38% |
| 2011 Q3 | 18.53 Million USD | -9.98% |
| 2011 FY | 16.24 Million USD | 1686.8% |
| 2011 Q1 | 22.32 Million USD | 2356.11% |
| 2011 Q2 | 20.59 Million USD | -7.78% |
| 2010 FY | 909 Thousand USD | -35.21% |
| 2010 Q1 | 1.27 Million USD | -8.91% |
| 2010 Q2 | 1.03 Million USD | -19.09% |
| 2010 Q3 | 1.03 Million USD | 0.29% |
| 2010 Q4 | 909 Thousand USD | -12.34% |
| 2009 Q1 | 1.5 Million USD | -17.45% |
| 2009 Q3 | 1.46 Million USD | -3.17% |
| 2009 Q4 | 1.4 Million USD | -4.23% |
| 2009 Q2 | 1.51 Million USD | 0.27% |
| 2009 FY | 1.4 Million USD | -23.25% |
| 2008 Q2 | 2.99 Million USD | -18.88% |
| 2008 FY | 1.82 Million USD | -50.45% |
| 2008 Q1 | 3.68 Million USD | -0.05% |
| 2008 Q3 | 2.29 Million USD | -23.24% |
| 2008 Q4 | 1.82 Million USD | -20.38% |
| 2007 Q4 | 3.68 Million USD | -8.35% |
| 2007 FY | 3.68 Million USD | -15.83% |
| 2007 Q2 | 4.04 Million USD | -4.31% |
| 2007 Q3 | 4.02 Million USD | -0.4% |
| 2007 Q1 | 4.22 Million USD | -3.65% |
| 2006 Q3 | 4.98 Million USD | -6.1% |
| 2006 Q1 | 5.25 Million USD | -1.59% |
| 2006 Q2 | 5.31 Million USD | 1.18% |
| 2006 Q4 | 4.38 Million USD | -12.15% |
| 2006 FY | 4.38 Million USD | -17.86% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q4 | 5.33 Million USD | 0.0% |
| 2005 FY | 5.33 Million USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2003 FY | - USD | -100.0% |
| 2003 Q1 | 2.95 Million USD | -40.31% |
| 2003 Q2 | 1.86 Million USD | -36.88% |
| 2003 Q4 | - USD | 0.0% |
| 2003 Q3 | - USD | -100.0% |
| 2002 Q4 | 4.95 Million USD | 0.0% |
| 2002 FY | 4.95 Million USD | 98.16% |
| 2002 Q1 | 900 Thousand USD | -64.01% |
| 2002 Q2 | - USD | -100.0% |
| 2002 Q3 | - USD | 0.0% |
| 2001 Q1 | 7.6 Million USD | -24.0% |
| 2001 Q4 | 2.5 Million USD | -43.16% |
| 2001 Q3 | 4.4 Million USD | -33.33% |
| 2001 Q2 | 6.6 Million USD | -13.16% |
| 2001 FY | 2.5 Million USD | -74.99% |
| 2000 Q1 | 4.84 Million USD | -18.42% |
| 2000 Q4 | 10 Million USD | -17.36% |
| 2000 Q2 | 4.19 Million USD | -13.26% |
| 2000 FY | 10 Million USD | 68.52% |
| 2000 Q3 | 12.1 Million USD | 188.16% |
| 1999 Q4 | 5.93 Million USD | -30.19% |
| 1999 FY | 5.93 Million USD | 91.42% |
| 1999 Q2 | 1.8 Million USD | 5.88% |
| 1999 Q3 | 8.5 Million USD | 372.22% |
| 1999 Q1 | 1.7 Million USD | -45.16% |
| 1998 Q3 | 5.6 Million USD | 0.0% |
| 1998 Q4 | 3.1 Million USD | -44.64% |
| 1998 FY | 3.1 Million USD | -44.64% |
| 1998 Q2 | - USD | 0.0% |
| 1998 Q1 | - USD | -100.0% |
| 1997 FY | 5.6 Million USD | 0.0% |
| 1997 Q1 | - USD | 0.0% |
| 1997 Q2 | - USD | 0.0% |
| 1997 Q3 | 7.5 Million USD | 0.0% |
| 1997 Q4 | 5.6 Million USD | -25.33% |
| 1996 Q3 | - USD | 0.0% |
| 1996 Q2 | - USD | 0.0% |
| 1996 Q1 | - USD | 0.0% |
| 1996 Q4 | - USD | 0.0% |
| 1996 FY | - USD | 0.0% |
| 1995 Q4 | - USD | 0.0% |
| 1995 Q1 | 400 Thousand USD | 0.0% |
| 1995 Q2 | - USD | -100.0% |
| 1995 Q3 | - USD | 0.0% |
| 1995 FY | - USD | 0.0% |
| 1994 Q3 | - USD | 0.0% |
| 1994 Q4 | - USD | 0.0% |
| 1994 Q1 | - USD | 0.0% |
| 1994 FY | - USD | 0.0% |
| 1994 Q2 | - USD | 0.0% |
| 1993 Q3 | - USD | 0.0% |
| 1993 Q2 | - USD | 0.0% |
| 1993 Q1 | - USD | 0.0% |
| 1993 Q4 | - USD | 0.0% |
| 1993 FY | - USD | 0.0% |
| 1992 Q2 | - USD | 0.0% |
| 1992 Q1 | - USD | 0.0% |
| 1992 FY | - USD | 0.0% |
| 1992 Q4 | - USD | 0.0% |
| 1992 Q3 | - USD | 0.0% |
| 1991 Q1 | - USD | 0.0% |
| 1991 FY | - USD | 0.0% |
| 1991 Q2 | - USD | 0.0% |
| 1991 Q3 | - USD | 0.0% |
| 1991 Q4 | - USD | 0.0% |
| 1990 Q3 | - USD | -100.0% |
| 1990 Q4 | - USD | 0.0% |
| 1990 Q2 | 100 Thousand USD | 0.0% |
| 1990 Q1 | 100 Thousand USD | 0.0% |
| 1990 FY | - USD | -100.0% |
| 1989 FY | 100 Thousand USD | -87.5% |
| 1989 Q2 | 200 Thousand USD | 0.0% |
| 1989 Q3 | 100 Thousand USD | -50.0% |
| 1989 Q4 | 100 Thousand USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 75.25 Million USD | 99.608% |
| AngioDynamics, Inc. | 3.93 Million USD | 92.511% |
| AtriCure, Inc. | 60.59 Million USD | 99.513% |
| Avinger, Inc. | - USD | -Infinity% |
| Azenta, Inc. | 60.43 Million USD | 99.512% |
| BioLife Solutions, Inc. | 18.31 Million USD | 98.389% |
| The Cooper Companies, Inc. | 2.52 Billion USD | 99.988% |
| Daxor Corporation | 755.65 Thousand USD | 60.961% |
| Ekso Bionics Holdings, Inc. | 4.83 Million USD | 93.895% |
| Femasys Inc. | 4.25 Million USD | 93.072% |
| GlucoTrack, Inc. | 196 Thousand USD | -50.51% |
| Harvard Bioscience, Inc. | 30.7 Million USD | 99.039% |
| Hologic, Inc. | 2.49 Billion USD | 99.988% |
| ICU Medical, Inc. | 1.57 Billion USD | 99.981% |
| Intuitive Surgical, Inc. | -82.1 Million USD | 100.359% |
| KORU Medical Systems, Inc. | 3.65 Million USD | 91.924% |
| LeMaitre Vascular, Inc. | 16.62 Million USD | 98.225% |
| Innovative Eyewear, Inc. | - USD | -Infinity% |
| Innovative Eyewear, Inc. | - USD | -Infinity% |
| Masimo Corporation | 871.7 Million USD | 99.966% |
| Microbot Medical Inc. | 40 Thousand USD | -637.5% |
| Meihua International Medical Technologies Co., Ltd. | 4592.00 USD | -6324.216% |
| Merit Medical Systems, Inc. | 823.01 Million USD | 99.964% |
| Nephros, Inc. | 1.39 Million USD | 78.777% |
| NovoCure Limited | 596.24 Million USD | 99.951% |
| NEXGEL, Inc. | 513 Thousand USD | 42.495% |
| NEXGEL, Inc. | 513 Thousand USD | 42.495% |
| Singular Genomics Systems, Inc. | 67.52 Million USD | 99.563% |
| OraSure Technologies, Inc. | 11.38 Million USD | 97.41% |
| Pro-Dex, Inc. | 7.53 Million USD | 96.085% |
| Pulse Biosciences, Inc. | 8.08 Million USD | 96.352% |
| Predictive Oncology Inc. | 2.18 Million USD | 86.523% |
| Precision Optics Corporation, Inc. | 1.93 Million USD | 84.778% |
| QuidelOrtho Corporation | 2.27 Billion USD | 99.987% |
| Repligen Corporation | 510.14 Million USD | 99.942% |
| Sanara MedTech Inc. | 9.11 Million USD | 96.763% |
| STAAR Surgical Company | 31.46 Million USD | 99.063% |
| Sharps Technology, Inc. | - USD | -Infinity% |
| DENTSPLY SIRONA Inc. | 1.79 Billion USD | 99.984% |
| Jin Medical International Ltd. | - USD | -Infinity% |